The question becomes why was the discussion in a closed-door meeting? I am leaning more towards they were discussing NWBO's DCVAX-L. While these CHM minutes often do not divulge a lot unlike FDA's ADcoms, the fact that it was closed-door makes me wonder if the discussion was related to DCVax-L's MAA status and more so the final classification full/conditional and the terms of the Label. I think those things could be deemed " confidential" and prejudice the commercial interest of NWBO. You have to wonder why does it explicitly state that information is being withheld under section 43 of the Freedom of Information Act.
Market Data 
Markets 
AI
